AHR

36 programs · 36 companies

Programs
36
Companies
36
Active Trials
20
Targeting AHR
DrugCompanyPhaseMOAIndications
PFE-2901PfizerPhase 2SOS1iSMACLL
AZN-1715AstraZenecaPhase 3FXIaiSMAPsoriasis
BAY-6520BayerPhase 2TROP-2 ADCFSGS
SemasacituzumabJazz PharmaPhase 2AuroraAiGBMPNH
DoxalemzoparlimabNuvalentApprovedSTINGagWMADHD
CRS-184CRISPR TherapeuticsPhase 1/2GLP-1agPompeMelanoma
TerazumabRecursionPhase 3BCMA ADCMSHemophilia A
DAW-5540Day One BioPhase 2KRASG12DiALSGastric Ca
LiralucimabArcturusPhase 2SOS1iGISTPompe
MavulucimabCSL LimitedNDA/BLAPD-1iPompeThymoma
ASL-9777Aslan PharmaPhase 2EGFRiUC
MAY-IIT-516Mayo ClinicPhase 3CAR-T CD19ALS
NIA-IIT-611NIAIDPhase 2FcRniCrohn's
CAM-IIT-240CAMSNDA/BLARAS(ON)iET
UCS-IIT-265UCSFPhase 3EZH2iThymoma
ZoriosocimabAsklepios BioApprovedCD47iMGMDD
ZanulemzoparlimabMorphic Ther (Lilly)Phase 3CD3xCD20FTDPBC
WIN-5410Windtree TherapeuticsNDA/BLASOS1iHCC
KemamavacamtenCelgene (BMS)PreclinicalIL-17iMCLBCC
SHI-2989Shire (Takeda)Phase 2STINGagADPKDGA
NidatenlimabABL BioApprovedMDM2iBCC
DarasertibMiNT TherPhase 1/2MDM2iMigraine
TRE-5650TreelinePhase 1/2SGLT2iUrothelial CaCKD
NiraglumideDecipheraPreclinicalCD3xCD20CMLPancreatic Ca
BIO-5105BioconPhase 3ALKiNMOSD
DatotapinarofAurobindoPhase 1AuroraAiThymoma
LAU-4167Laurus LabsNDA/BLAMDM2iSCDFSGS
TRI-2500Trillium (Pfizer)Phase 1/2USP1iWilmsCeliac
IvomavacamtenExact SciencesPhase 1/2GLP-1/GIPFabryPSP
SUV-4226Suven PharmaPhase 3BCL-2iMelanoma
TixalucimabAche LaboratoriosApprovedALKiMG
BIO-IIT-877Bio-ManguinhosPreclinicalCDK4/6iSCLC
NidaratamabMega LifesciencesPreclinicalAHRantCF
CAM-IIT-192CAMS Peking UnionPhase 2JAK1/2iALS
IDX-785IDEXX LaboratoriesPhase 1JAK1/2iCrohn's
DNA-3921Ginkgo BioworksNDA/BLATROP-2 ADCPsoriasisRett